Studije o sprovođenju mera prevencije kardiovaskularnih bolesti bolest bolesti pokazala je visoku prevalencu štetnih karakteristika stila života, drugih faktora rizika i nedovoljne upotrebe profilaktičkih lekova kod bolesnika sa aterosklerotskom bolešču.Postojale su značajne varijacije kod načina života bolesnika,naročito u vezi pušenja i upotrebe nekih profilaktičkih lijekova.načn života,ciljen vrijednosti faktora rizika i terapeutski ciljevi prema zajedničkim evropskim preporukama nisu realizovani kod većine bolesnika u Evropi.U novim preporukama bolesnii sa veoma visokim rizikom za koronarnu bolest ciljna vrijednost LDL< 1.4 mmol/l ili redukcija najmanje 50% ako je bazalna vrijednost od 1.8 do 3.5mmol/l.U bolesnika sa veoma visokim rizikom, sa stalno povišenim LDL uprkos maksimalnoj dozi statina, u kombinaciji sa ezetemidom ili kod onih koji ne tolerišu statin potrebno je uvesti PCSK9 inhibitore. Značaj pokretanja odgovarajuće prevenciju prije otpuštanju iz bolnice ne može biti zanemarena, kao i liječenje, prevencija smanjuje post-hospitalizaciju sa povećanjem broja pacijenata koji su na odgovarajućujoj terapiji i koji dostižu ciljne vrijednosti faktora rizika. Ovo podrazumjeva potpunu kliničku procjenu koja vodi optimizacije medicinske terapije, individualnoj edukaciji za promjenu ponašanja i modifikaciju faktora rizika. Specijalizovani programi prevencije i konsultacije pacijenata treba da koriste pristup na pacijentu koji se fokusira na prioritete i ciljeve pacijenta i uključuje promjene načina života u kontekstu života bolesnika. Klinički stručnjaci i ljekari opšte medicine treba da usklade svoje napore, i uz podršku drugih zdravstvenih stručnjaka naprave integrisanu kliničku strategiju za prevenciju koronarne u bolnicama i zajednici . Ključne riječi: prevencija kardiovaskularna bolest
Visseren FLJ, Mach F, Smulders YM. Carballo KC et al.2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;7;42(34):3227-3337.
3.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;
4.
Kotseva K, Backer G, Bacquer D, Rydén L, Hoes A, Grobbee D, et al.
5.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018;
6.
Bacquer D, Smedt D, K K, C J, D W, L R, et al. EUROASPIRE Investigators..Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. Eur J Epidemiol. 2018;
7.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. ODYSSEY OUTCOMES Committees and Investigators.
8.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. FOURIER Steering Committee and Investigators. In: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
9.
Landmesser U, Chapman MG, Borén SJkaJP, JB FMBAF, S G, I. Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia,Eur.Heart J. Apr. 2017;7;39(14):1131-1143.
10.
Kotseva K, Bacquer D, Backer G, Rydén L, Jennings C, Gyberg V, et al. :Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions, Eur J Prev Cardiol. 2016;23(18):2007–18.
11.
Piepoli FM, Corra U, all DP. Challlenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol. 2016;
12.
Vulić D, Djekić D. Šta je novo u sekundarnoj prevenciji koronarnih bolesnika u Republici Srpskoj-rezultati ROSCOPS V, Zbornik radova i sažetaka IV Kongresa kardiologa Republike Srpske,2016.
13.
Piepol FM. Hoes WA,Agewall S et all.2016 ESC Prevention Guidelines 2016. Eur Heart J. 2016;37(29):2315–81.
14.
Gyberg V, Bacquer D, Backer G, Jennings C, Kotseva K, Mellbin L, et al. EUROASPIRE Investigators: Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;1;14(1):133.
15.
Lifestyle and risk factor menagement and use of the drug therapies in coronary patients from 15 countries: pricipal results from EUROSPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–72.
16.
Vulić D. Šormaz Lj: Implementacija mera sekundarne prevencije koronarne bolesti u kliničkoj praksi,Balneoklimatologija,septembar 2013,37,2,169-177.
17.
18.
Wong ND, Vulic D, Sobot M. Implementation of Secondary Prevention Methodologies in Ischemic Heart Disease,Scrip. 2010;1:29–35.
19.
Vulic D, Loncar S, Krneta M. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska. In: Bosnia and Herzegovina in 2005-2006,Arch Med. 2010. p. 183–7.
20.
Kotseva K, Wood D, Backer G, Bacquer D, Pyorala K, U K, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II. III surveys in eight European countries Lancet. 2009;373:929–40.
21.
Kotseva K, Wood D, Backer G, Bacquer D, Pyorala K, U K, et al. EUROASPIRE III: A surve y on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty-two European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121–37.
22.
Vulić D, Ostojić M, Marinković J. Primarna i sekundarna prevencija ateroskleroze, Novi pogledi u prevenciji i tretmanu ateroskleroze. 2007.
23.
Graham I, Atar D, Borch-Johnsen. European Guidelines on Cardiovascular Diseases Prevention in clinical practice: full text.Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in clinical practice.Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):51–113.
24.
SC S, RO B, MA C. Gibbons R al: lNational Heart,Lung, and Blood Institute. AHA/ACC Guidelines for Secondary Prevention Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update. Circulation. 2011;124:00–00.
25.
EUROSPIRE II group.Lifestyle and risk factor management and use of drug theraoies in coronary patients from 15 countries.Principal results from. EUROSPIRE IIEu Heart J. 2001;22:554–72.
26.
EUROSPIRE II Group.Clinical reality of coronary prevention guidelines:a comparation:a compartion of EUROSPIRE I and II survey in nine countries. Lancet. 2001;357:997–1003.
27.
Clinical reality of coronary prevention guidelines: a comparation of EUROSPIRE I and II in nine countries. , Lancet. 2001;357:995–1001.
28.
Wong N, Black H, Gardin J, Cardiology P, McGraw-Hill. Keys A. Seven Countries: A multivariate Analysis of Death and Coronary Disease. 2000.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
